These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 30610579)

  • 1. Precision medicine review: rare driver mutations and their biophysical classification.
    Nussinov R; Jang H; Tsai CJ; Cheng F
    Biophys Rev; 2019 Feb; 11(1):5-19. PubMed ID: 30610579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why Are Some Driver Mutations Rare?
    Nussinov R; Tsai CJ; Jang H
    Trends Pharmacol Sci; 2019 Dec; 40(12):919-929. PubMed ID: 31699406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers.
    Nussinov R; Jang H; Tsai CJ; Cheng F
    PLoS Comput Biol; 2019 Mar; 15(3):e1006658. PubMed ID: 30921324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data.
    Wang E; Zaman N; Mcgee S; Milanese JS; Masoudi-Nejad A; O'Connor-McCourt M
    Semin Cancer Biol; 2015 Feb; 30():4-12. PubMed ID: 24747696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.
    Cheng F; Hong H; Yang S; Wei Y
    Brief Bioinform; 2017 Jul; 18(4):682-697. PubMed ID: 27296652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles.
    Wang L; Li F; Sheng J; Wong ST
    BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S6. PubMed ID: 26099165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting rare driver mutations for precision cancer medicine.
    Scholl C; Fröhling S
    Curr Opin Genet Dev; 2019 Feb; 54():1-6. PubMed ID: 30844512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finding cancer driver mutations in the era of big data research.
    Poulos RC; Wong JWH
    Biophys Rev; 2019 Feb; 11(1):21-29. PubMed ID: 29611034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine Learning Classification and Structure-Functional Analysis of Cancer Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes.
    Agajanian S; Odeyemi O; Bischoff N; Ratra S; Verkhivker GM
    J Chem Inf Model; 2018 Oct; 58(10):2131-2150. PubMed ID: 30253099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of activation and the rewired network: New drug design concepts.
    Nussinov R; Zhang M; Maloney R; Tsai CJ; Yavuz BR; Tuncbag N; Jang H
    Med Res Rev; 2022 Mar; 42(2):770-799. PubMed ID: 34693559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes.
    Cheng F; Zhao J; Zhao Z
    Brief Bioinform; 2016 Jul; 17(4):642-56. PubMed ID: 26307061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy.
    Ding XX; Zhu QG; Zhang SM; Guan L; Li T; Zhang L; Wang SY; Ren WL; Chen XM; Zhao J; Lin S; Liu ZZ; Bai YX; He B; Zhang HQ
    Oncotarget; 2017 Aug; 8(33):55715-55730. PubMed ID: 28903454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biophysical and Mechanistic Models for Disease-Causing Protein Variants.
    Stein A; Fowler DM; Hartmann-Petersen R; Lindorff-Larsen K
    Trends Biochem Sci; 2019 Jul; 44(7):575-588. PubMed ID: 30712981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming Cancer Prevention through Precision Medicine and Immune-oncology.
    Kensler TW; Spira A; Garber JE; Szabo E; Lee JJ; Dong Z; Dannenberg AJ; Hait WN; Blackburn E; Davidson NE; Foti M; Lippman SM
    Cancer Prev Res (Phila); 2016 Jan; 9(1):2-10. PubMed ID: 26744449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome sequencing analysis of liver cancer for precision medicine.
    Nakagawa H; Fujita M; Fujimoto A
    Semin Cancer Biol; 2019 Apr; 55():120-127. PubMed ID: 29605648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein Structure Readouts of Cancer Drivers for Precision Medicine.
    Dhanjal JK; Kalra RS
    Curr Protein Pept Sci; 2022; 23(3):158-165. PubMed ID: 35331108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoinhibition can identify rare driver mutations and advise pharmacology.
    Nussinov R; Tsai CJ; Jang H
    FASEB J; 2020 Jan; 34(1):16-29. PubMed ID: 31914624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS mutations in human cancers: Roles in precision medicine.
    Murugan AK; Grieco M; Tsuchida N
    Semin Cancer Biol; 2019 Dec; 59():23-35. PubMed ID: 31255772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovering personalized driver mutation profiles of single samples in cancer by network control strategy.
    Guo WF; Zhang SW; Liu LL; Liu F; Shi QQ; Zhang L; Tang Y; Zeng T; Chen L
    Bioinformatics; 2018 Jun; 34(11):1893-1903. PubMed ID: 29329368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.